Israel - English - Ministry of Health

teva israel ltd - deferasirox - tablets dispersible - deferasirox 500 mg - deferasirox - deferasirox teva is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). deferasirox teva is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [lic] ≥5 mg fe/g dry weight [dw] or serum ferritin consistently >800 μg /l).lic is the preferred method of iron overload determination and should be used wherever available.

Canada - English - Health Canada

pharmascience inc - deferasirox - tablet - 90mg - deferasirox 90mg

Canada - English - Health Canada

pharmascience inc - deferasirox - tablet - 180mg - deferasirox 180mg

Canada - English - Health Canada

pharmascience inc - deferasirox - tablet - 360mg - deferasirox 360mg

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - deferasirox - iron overload; beta-thalassemia - iron chelating agents - deferasirox mylan is indicated forthe treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and olderthe treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - deferasirox - iron overload; beta-thalassemia - all other therapeutic products, iron chelating agents - deferasirox accord is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.deferasirox accord is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in paediatric patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years,in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (

Canada - English - Health Canada

apotex inc - deferasirox - tablet for suspension - 125mg - deferasirox 125mg - heavy metal antagonists

Canada - English - Health Canada

apotex inc - deferasirox - tablet for suspension - 250mg - deferasirox 250mg - heavy metal antagonists

Canada - English - Health Canada

apotex inc - deferasirox - tablet for suspension - 500mg - deferasirox 500mg - heavy metal antagonists

Canada - English - Health Canada

taro pharmaceuticals inc - deferasirox - tablet for suspension - 125mg - deferasirox 125mg - heavy metal antagonists